Cancer Management and Research (Dec 2019)

Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

  • Vergnenègre A,
  • Basse V,
  • Le Garff G,
  • Bylicki O,
  • Dubos-Arvis C,
  • Comet B,
  • Marcq M,
  • Le Treut J,
  • Auliac JB,
  • Madroszyk A,
  • Fraboulet G,
  • Crequit J,
  • Thomas P,
  • Paleiron N,
  • Monnet I

Journal volume & issue
Vol. Volume 11
pp. 10821 – 10826

Abstract

Read online

Alain Vergnenègre,1 Victor Basse,2 Gwenaelle Le Garff,3 Olivier Bylicki,4 Catherine Dubos-Arvis,5 Bénédicte Comet,6 Marie Marcq,7 Jacques Le Treut,8 Jean-Bernard Auliac,9 Anne Madroszyk,10 Gislaine Fraboulet,11 Jacky Crequit,12 Pascal Thomas,13 Nicolas Paleiron,14 Isabelle Monnet15 On behalf of the French Lung Cancer Group1Centre Hospitalier Universitaire (CHU) Dupuytren, Limoges, France; 2CHU Morvan, Brest, France; 3CH Yves-Le-Foll, Saint-Brieuc, France; 4Hôpital d’Instruction des Armées Percy, Clamart, France; 5Centre François-Baclesse, Caen, France; 6Centre Catalan d’Oncologie, Perpignan, France; 7CH Départemental Vendée, Les Oudairies, La Roche-Sur-Yon, France; 8CH du Pays d’Aix, Aix-En-Provence, France; 9Hôpital Quesnay, Mantes-La-Jolie, France; 10Institut Paoli-Calmettes, Marseille, France; 11CH René-Dubos, Cergy-Pontoise, France; 12CH Laennec, Creil, France; 13CH Intercommunal (CHI) Des Alpes-Du-Sud, Gap, France; 14Hôpital d’Instruction Des Armées Sainte-Anne, Toulon, France; 15CHI Créteil, Créteil, FranceCorrespondence: Alain VergnenègreUnité d’Oncologie Thoracique et Cutanée, CHU de Limoges Hôpital Dupuytren, 2, Avenue Martin-Luther-King, Limoges Cedex 87042, FranceTel +33 5 55 05 62 13Fax +33 5 55 05 64 17Email [email protected]: Antiangiogenic agents have improved the prognosis of non-squamous non-small–cell lung cancers (NSCLCs), even though all the patients are not eligible to receive them because of counterindications linked to the tumor’s characteristics or comorbidities. Much less information is available about the eligibility of patients with squamous non-small–cell lung cancers (SQ-NSCLCs) to receive antivascular endothelial growth-factor (VEGF) treatments, even though such molecules are being developed for this histology. This study was undertaken to determine the percentage of advanced SQ-NSCLC patients who would be eligible to receive an antiVEGF agent as second-line systemic therapy.Methods: This observational, multicenter, prospective study evaluated advanced SQ-NSCLC patients’ criteria for ineligibility to receive an antiVEGF during a multidisciplinary meeting to choose their standard second-line systemic therapy.Results: Among the 317 patients included, 53.6% had at least one ineligibility criterion, and ∼20% had at least two, with disease extension to large vessels (39.8%), tumor cavitation (20.5%), cardiovascular disease (11%) and/or hemoptysis (7.2%) being the most frequent. Patients with an ECOG performance score of 1/2 had more cardiovascular contraindications that those with scores of 0.Conclusion: Almost half of the SQ-NSCLC patients included in this study would have been eligible to receive an antiVEGF agent. The development of these molecules for these indications should be encouraged.Keywords: lung cancer, squamous non-small cell, antiangiogenic treatments

Keywords